Biotech Values

[DewDiligence]

Re: HCV longevity

Maybe just a bit premature to jump to any conclusions about long-term sustainability at this point? Pretty uncritical thinking, IMHO.

Perhaps you read my post too quickly. What I assert (in #msg-101786038) is that the new all-oral regimens will not exhibit an Incivek-like boom & bust—i.e. a parabolic rise followed by a full-blown crash about a year later.

Does anyone really think that pattern is what’s in store for the new all-oral HCV regimens? If so, please reread the post by ‘justpaul’ in #msg-99063292.